Cotellic 20 Mg 20 mg FC tablets
PDF Leaflet Revision Date: 15 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of unresectable or metastatic melanoma with BRAF V600 mutation.
Dosage (summary)
60 mg (3 tablets) once daily for 21 days, followed by a 7-day break.
Special Populations
- Geriatric use
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; contraindicated in breastfeeding.
Key Drug Interactions
- CYP3A inhibitors
- CYP3A inducers
Contraindications
- Hypersensitivity to cobimetinib or excipients
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Photosensitivity
Counselling Points
- Avoid sun exposure
- Use effective contraception
- Monitor for visual disturbances
Serious warnings
- New primary malignancies
- Severe dermatologic reactions
- Haemorrhage
- Left ventricular dysfunction
Important Disclaimer
The Cotellic 20 Mg 20 mg FC tablets professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
